Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VRVg-2 · 1 trial · 1 indication
RVNA titer against rabies virus was assessed using the Rapid Fluorescent Focus Inhibition test (RFFIT) assay method.
| Arm | Type | Description |
|---|---|---|
| Group 1: VRVg-2 + HRIG | EXPERIMENTAL | Participants received 0.5 milliliters (mL) intramuscular (IM) injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0. |
| Group 2: Verorab + HRIG | ACTIVE_COMPARATOR | Participants received 0.5 mL IM injection of Verorab on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0. |
| Group 3: Imovax Rabies + HRIG | ACTIVE_COMPARATOR | Participants received 1 mL IM injection of Imovax Rabies on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0. |
| Group 4: VRVg-2 | EXPERIMENTAL | Participants received 0.5 mL IM injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28. |
| Name | Type | Description |
|---|---|---|
| VRVg-2 | BIOLOGICAL | Pharmaceutical form: Powder and solvent for suspension for injection; Route of administration: IM |
| Purified Inactivated Rabies Vaccine | BIOLOGICAL | Pharmaceutical form: Powder and solvent for suspension for injection; Route of administration: IM |
| Human Diploid Cell Vaccine (HDCV) | BIOLOGICAL | Pharmaceutical form: Powder and solvent for suspension for injection; Route of administration: IM |
| Rabies immune globulin (human) | BIOLOGICAL | Pharmaceutical form: Solution for injection; Route of administration: IM |
Inclusion criteria : * Men or women aged \>=18 years on the day of inclusion (\>= 18 years means from the day of the 18th birthday onwards, with no upper age limit). * Able to attend all scheduled visits and to comply with all trial procedures. * Body Mass Index (BMI): 18.5 kilograms per square met...
VRVg 2 is a purified Vero rabies vaccine being developed by Sanofi for the prevention of rabies virus infection. It is intended for use in healthy volunteers and is currently in clinical development for rabies prophylaxis.
VRVg 2 is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
VRVg 2 is in Phase 2 clinical development. It has completed a Phase 2 trial and a Phase 3 trial, both of which are finished. The vaccine is investigational and has not been approved by regulatory authorities.
VRVg 2 has been studied in two completed trials. NCT03145766 was a Phase 2 trial in the United States with 320 participants, and NCT03965962 was a Phase 3 trial in France with 640 participants, both involving healthy adults aged 18 years and older.
VRVg 2 is a monoclonal antibody vaccine that works by stimulating the immune system to produce antibodies against the rabies virus. It is designed to provide protection against rabies infection when administered before or after exposure.
Yes, VRVg 2 is a purified Vero rabies vaccine. It is manufactured using Vero cells, a standard cell line used for vaccine production, and is being developed as a potential rabies vaccine for human use.